OFIXOrthofix Medical Inc. exhibits mixed performance. Fundamentally, the company is navigating challenges with negative earnings and free cash flow, though revenue has shown some recent growth. Thematic alignment with medical technology is positive. Technical indicators show some bullish signs in the short term but also overbought conditions.
Orthofix operates in the medical technology sector, which generally benefits from aging populations, increased healthcare spending, and technological advancements. The company's focus on spine and orthopedic solutions places it within a growing market segment.
Financially, Orthofix has shown negative earnings and free cash flow in recent periods, indicating profitability challenges. While revenue has seen some quarterly increases, sustained profitability and positive cash generation are key areas for improvement.
Short-term technical indicators suggest a cautiously bullish stance. The stock has seen recent price appreciation, with many moving averages indicating a buy signal. However, some oscillators are in overbought territory, hinting at potential consolidation.
| Factor | Score |
|---|---|
| Healthcare Sector Growth | 80 |
| Innovation in Medical Devices | 75 |
| Regulatory Landscape | 60 |
| Competition | 65 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 20 |
| Growth | 70 |
| Balance Sheet Health | 60 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 55 |
| Volume Confirmation | 65 |
| Support & Resistance | 60 |
Positive Earnings Surprises
The company has consistently beaten EPS estimates in the last several quarters (e.g., Q2 2025 estimate -0.27 vs. reported -0.08, surprise 70.0%; Q1 2025 estimate -0.05 vs. reported 0.01, surprise 120.0%). This demonstrates an ability to manage operations effectively and exceed market expectations.
Improving Cash Position and Reduced Debt
While Q4 2024 shows higher debt than Q4 2023, the operating cash flow for Q4 2024 turned positive ($23.73M) compared to negative in Q4 2023 (-$45.75M). The end cash position has also improved to $85.74M in Q4 2024 from $37.76M in Q4 2023.
Consistent Net Losses and Negative EPS
The company has consistently reported negative net income and EPS (e.g., TTM net income of -$109.63M, EPS of -3.7). This indicates ongoing operational losses and a lack of profitability, posing a significant risk to investors.
Increasing Debt and Negative Free Cash Flow
Total debt has increased from $117.07M in Q4 2023 to $179.63M in Q4 2024. Furthermore, free cash flow has been negative for multiple periods (e.g., -$9.09M in Q4 2024, -$107.80M in Q4 2023), signaling potential cash burn and funding challenges.
August 2025
5
Next Earnings Date
H: $0.04
A: $0.04
L: $0.04
H: 199.87M
A: 196.89M
L: 196.00M
Orthofix Medical Inc. operates as a medical technology company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulation devices that enhance bone fusion, including adjunctive and noninvasive treatment of the cervical and lumbar spine, as well as a therapeutic treatment for non-spinal, appendicular fractures, and fresh fractures that have not healed; designs, develops, and markets a portfolio of spine fixation and motion preservation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and provides 7D flash navigation system for spine and cranial procedures. Its Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
22.30 USD
The 39 analysts offering 1 year price forecasts for OFIX have a max estimate of 27.20 and a min estimate of 16.00.